These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
334 related items for PubMed ID: 10469452
41. Gene expression profiling detects gene amplification and differentiates tumor types in breast cancer. Dressman MA, Baras A, Malinowski R, Alvis LB, Kwon I, Walz TM, Polymeropoulos MH. Cancer Res; 2003 May 01; 63(9):2194-9. PubMed ID: 12727839 [Abstract] [Full Text] [Related]
42. The genomic profile of HER2-amplified breast cancers: the influence of ER status. Marchiò C, Natrajan R, Shiu KK, Lambros MB, Rodriguez-Pinilla SM, Tan DS, Lord CJ, Hungermann D, Fenwick K, Tamber N, Mackay A, Palacios J, Sapino A, Buerger H, Ashworth A, Reis-Filho JS. J Pathol; 2008 Dec 01; 216(4):399-407. PubMed ID: 18810758 [Abstract] [Full Text] [Related]
43. ERBB-2 (HER2/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer. Szöllösi J, Balázs M, Feuerstein BG, Benz CC, Waldman FM. Cancer Res; 1995 Nov 15; 55(22):5400-7. PubMed ID: 7585609 [Abstract] [Full Text] [Related]
44. Topoisomerase-II alpha is upregulated in malignant peripheral nerve sheath tumors and associated with clinical outcome. Skotheim RI, Kallioniemi A, Bjerkhagen B, Mertens F, Brekke HR, Monni O, Mousses S, Mandahl N, Soeter G, Nesland JM, Smeland S, Kallioniemi OP, Lothe RA. J Clin Oncol; 2003 Dec 15; 21(24):4586-91. PubMed ID: 14673046 [Abstract] [Full Text] [Related]
45. c-erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine-needle aspirates. Mezzelani A, Alasio L, Bartoli C, Bonora MG, Pierotti MA, Rilke F, Pilotti S. Br J Cancer; 1999 May 15; 80(3-4):519-25. PubMed ID: 10408862 [Abstract] [Full Text] [Related]
46. New understanding of the role of anthracyclines in early-stage breast cancer: patient selection considerations. Gennari A, Pronzato P. Clin Breast Cancer; 2008 Dec 15; 8 Suppl 4():S179-83. PubMed ID: 19158039 [Abstract] [Full Text] [Related]
50. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma. Couturier J, Vincent-Salomon A, Nicolas A, Beuzeboc P, Mouret E, Zafrani B, Sastre-Garau X. Mod Pathol; 2000 Nov 15; 13(11):1238-43. PubMed ID: 11106082 [Abstract] [Full Text] [Related]
52. Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers. Grushko TA, Blackwood MA, Schumm PL, Hagos FG, Adeyanju MO, Feldman MD, Sanders MO, Weber BL, Olopade OI. Cancer Res; 2002 Mar 01; 62(5):1481-8. PubMed ID: 11888924 [Abstract] [Full Text] [Related]
53. Amplification of the c-erbB-2 (HER-2/neu) gene in gastric cancer cells. Detection by fluorescence in situ hybridization. Ishikawa T, Kobayashi M, Mai M, Suzuki T, Ooi A. Am J Pathol; 1997 Sep 01; 151(3):761-8. PubMed ID: 9284825 [Abstract] [Full Text] [Related]
57. Predictive value of HER-2 and Topoisomerase IIalpha in response to primary doxorubicin in breast cancer. Arriola E, Moreno A, Varela M, Serra JM, Falo C, Benito E, Escobedo AP. Eur J Cancer; 2006 Nov 01; 42(17):2954-60. PubMed ID: 16935488 [Abstract] [Full Text] [Related]
58. Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes. Olsen KE, Knudsen H, Rasmussen BB, Balslev E, Knoop A, Ejlertsen B, Nielsen KV, Schönau A, Overgaard J, Danish Breast Cancer Co-operative Group. Acta Oncol; 2004 Nov 01; 43(1):35-42. PubMed ID: 15068318 [Abstract] [Full Text] [Related]